Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;8(7):2463-2467.
doi: 10.4103/jfmpc.jfmpc_316_19.

A study to determine the prevalence, clinical profile and incidence of formation of inhibitors in patients of hemophilia in North Eastern part of India

Sandip Kumar  1 , Sachidanand Sinha  1 , Anju Bharti  1 , Lalit P Meena  2 , Vineeta Gupta  3 , Jyoti Shukla  1
Affiliations

A study to determine the prevalence, clinical profile and incidence of formation of inhibitors in patients of hemophilia in North Eastern part of India

Sandip Kumar et al. J Family Med Prim Care. 2019 Jul.

Abstract

Introduction: Deficiency of factor VIII (Hemophilia A), factor IX (Hemophilia B) and Von Willebrand's factor are the most frequent coagulation defects. The incidence of inhibitors in patients of factor VIII deficiency is varies in different regions of India.

Aim: To determine the prevalence, clinical profile and incidence of formation of inhibitors in patients of Hemophilia in north eastern part of India.

Methods: Selected patients were under went for complete Blood Count (CBC), General Blood Picture (GBP), Prothrombin time (PT), Activated partial thromboplastin time (APTT), Thrombin time, Correction experiment to know the specific factor deficiency or inhibitors present by Normal Plasma, Normal aged serum, Al(OH)3 adsorbed plasma.

Results: 92 patients diagnosed as suffering with Hemophilia A or B were included in study. The age of patients ranged from 2.5 month to 53 years. Out of 92, seventy nine (85.87%) were Haemophilia A and thirteen were (14.13%) Hemophilia B patients. 3.50% (2/55) cases of treated Hemophilia A patient develop inhibitor.

Conclusion: The prevalence of hemophilia and incidence of inhibitors in these patients is varies in different regions of India. This variation may be due to the type of product used as treatment, intensity of treatment or the genetic characteristics of the patients.

Keywords: Factor VIII; IX. Hemophilia; Inhibitors.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Measurement of factor VIII inhibitors
See this image and copyright information in PMC

References

    1. Baklaja R, Pešic’ MC, CzarneckiJ Hemostasis and hemorrhagic disorders.Germany: FermentationBiotecc GmbH. Rudolf-Huch-Str. 2008;14:68–153.
    1. Tirunagari S, Shaik D. Hemophilia and Acquired Hemophilia A. WebmedCentral Clinical Trials. 2013;4:WMC004048.
    1. John MJ, Tanuja T, Mathew A, Philip CC, Singh J, Dinakaran M, et al. Demographic profile and real world data of persons with hemophilia in a resource constrained setup. CHRISMED J Health Res. 2018;5:214–20.
    1. Schep SJ, Boes M, Schutgens REG, van Vulpen LFD. An update on the ‘danger theory’ in inhibitor development in haemophilia A. Expert Rev Hematol. 2019:1–10. doi: 10.1080/17474086.2019.1604213. [Epub ahead of print] - PubMed
    1. Pinto P, Shelar T, Nawadkar V, Mirgal D, Mukaddam A, Nair P, et al. The epidemiology of FVIII inhibitors in Indian haemophilia a patients. Indian J Hematol Blood Transfus. 2014;30:356–63. - PMC - PubMed